Related Experiment Video
Updated: Jun 9, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Impacts of anti-EGFR monoclonal antibody in prostate cancer PC3 cells
Alireza Rezaiemanesh1, Jafar Majidi, Behzad Baradaran
1Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:
Epidermal growth factor receptor (EGFR) network appears to be a rich target for prostate cancer. Thus, in this current investigation, to pursue our newly developed anti-EGFR monoclonal antibody (mAb) in prostate cancer, its inhibitory effect was investigated in PC3 cells. The binding specificity of antibody was examined by flow cytometry and immunofluorescence staining. The cultivated cells were treated with various doses of the anti-EGFR mAb at different time points and the cellular and/or molecular impacts were assessed. MTT assay was utilized to examine the cytotoxic effects. Semi-quantitative RT-PCR was used to evaluate the expression of EGFR and some important apoptosis signaling molecules (e.g., MAPK-1, STAT-5, Akt-1 kinase). Flow cytometric and immunofluorescence staining analyses showed that the anti-EGFR mAb can bind to EGFR with high specificity. The results revealed that the anti-EGFR mAb can inhibit cell growth in a dose and time dependent manner. RT-PCR analysis revealed that the binding of anti-EGFR mAb to its receptors can eventually result in downregulation of Akt-1 kinase gene, but not MAPK-1, STAT-5 and EGFR genes. Based on our findings, it can be concluded that Akt-1 is the most important downstream signaling molecules affected by anti-EGFR mAbs.
Insights
A new anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody effectively inhibits prostate cancer cell growth. This antibody specifically targets EGFR, downregulating the critical Akt-1 kinase signaling pathway.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- The Epidermal Growth Factor Receptor (EGFR) signaling pathway is a significant target in prostate cancer research.
- Developing targeted therapies against EGFR is crucial for effective prostate cancer treatment.
Purpose of the Study:
- To investigate the inhibitory effects of a newly developed anti-EGFR monoclonal antibody (mAb) on prostate cancer cells (PC3).
- To assess the specificity and downstream molecular impacts of anti-EGFR mAb treatment.
Main Methods:
- Flow cytometry and immunofluorescence staining to confirm antibody binding specificity to EGFR.
- MTT assay to evaluate the cytotoxic effects of the anti-EGFR mAb.
- Semi-quantitative RT-PCR to analyze gene expression of EGFR, MAPK-1, STAT-5, and Akt-1 kinase.
Main Results:
- The anti-EGFR mAb demonstrated high specificity in binding to EGFR on PC3 cells.
- Cell growth inhibition was observed in a dose- and time-dependent manner following mAb treatment.
- RT-PCR analysis indicated that anti-EGFR mAb binding downregulates the Akt-1 kinase gene, while not affecting MAPK-1, STAT-5, or EGFR gene expression.
Conclusions:
- The novel anti-EGFR mAb exhibits potent inhibitory effects on prostate cancer cell proliferation.
- Akt-1 kinase is identified as the primary downstream signaling molecule affected by this anti-EGFR mAb, suggesting its role in the observed anti-cancer activity.
